The DCC protein and prognosis in colorectal cancer.

TitleThe DCC protein and prognosis in colorectal cancer.
Publication TypeJournal Article
Year of Publication1996
AuthorsShibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, Jessup JM, Loda M, Summerhayes IC
JournalN Engl J Med
Date Published1996 Dec 05
KeywordsAged, Biomarkers, Tumor, Cell Adhesion Molecules, Colorectal Neoplasms, DCC Receptor, Female, Gene Expression, Genes, DCC, Humans, Immunohistochemistry, Life Tables, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Receptors, Cell Surface, Survival Rate, Tumor Suppressor Proteins

BACKGROUND: Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma.

METHODS: The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II and III colorectal carcinomas. The Cox proportional-hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy.

RESULTS: The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03).

CONCLUSIONS: DCC is a prognostic marker in patients with stage II or stage III colorectal cancer. In stage II colorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of patients.

Alternate JournalN Engl J Med
PubMed ID8929264
Grant ListCA-44704 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700